This is a phase III double-masked, randomized, controlled study evaluating the efficacy of
EBI-005 as compared to vehicle given as a topical ophthalmic solution in each eye to subjects
with moderate to severe DED three times daily for 12 weeks. Approximately 730 subjects at up
to approximately 50 centers in the United States will be screened, enrolled into the study.